Cue Biopharma (CUE) VP and Principal Accounting Officer files initial Form 3
Rhea-AI Filing Summary
Cue Biopharma, Inc. filed an initial Form 3 for officer Michael Vincent Meluzio, who serves as VP and Principal Accounting Officer. The filing reports that he is an officer but does not list any equity transactions or current holdings in either common stock or derivatives.
Positive
- None.
Negative
- None.
Key Terms
Form 3, beneficial ownership, Principal Accounting Officer
3 terms
Form 3 regulatory
"Cue Biopharma, Inc. filed an initial Form 3 for officer Michael Vincent Meluzio"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership financial
"It is an initial beneficial ownership report and does not list any specific share holdings"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Principal Accounting Officer financial
"serves as VP and Principal Accounting Officer"
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Form 3 filing for Cue Biopharma (CUE) disclose about Michael Vincent Meluzio?
The Form 3 shows that Michael Vincent Meluzio is an officer of Cue Biopharma, serving as VP and Principal Accounting Officer. It is an initial beneficial ownership report and does not list any specific share holdings or recent transactions in the company’s securities.
Does the Cue Biopharma (CUE) Form 3 show any stock purchases or sales by Michael Vincent Meluzio?
No, the Form 3 does not show any stock purchases or sales by Michael Vincent Meluzio. The transaction summary indicates zero buy, sell, exercise, gift, tax-withholding, or restructuring transactions, reflecting only his status as a reporting officer of Cue Biopharma.
Are any derivative securities reported for Michael Vincent Meluzio in Cue Biopharma’s Form 3?
No derivative securities are reported for Michael Vincent Meluzio in this Form 3. The derivativeSummary section is empty and the transactionSummary shows zero derivative transactions, indicating no options, warrants, or similar instruments are disclosed in this initial ownership statement.
What is Michael Vincent Meluzio’s role at Cue Biopharma (CUE) according to the Form 3?
According to the Form 3, Michael Vincent Meluzio is an officer of Cue Biopharma with the title VP, Principal Accounting Officer. This role means he is responsible for principal accounting functions and must report his beneficial ownership in the company’s securities to the SEC.
Does the Cue Biopharma (CUE) Form 3 indicate any significant insider activity?
The Form 3 does not indicate significant insider activity. All transaction counts and share amounts for buys, sells, exercises, gifts, tax withholding, and restructurings are zero, and netBuySellDirection is noted as neutral, reflecting the absence of reportable trades in this filing.